Crescendo Bioscience Announces Laboratory Clearance for Use of Vectra® DA in New York State
4/18/2013 11:21:59 AM
SOUTH SAN FRANCISCO, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- Crescendo Bioscience®, a molecular diagnostics company developing and commercializing quantitative, biology-based tests for rheumatoid arthritis (RA) and other autoimmune diseases, announced today that the Wadsworth Center at the New York Department of Health through its Clinical Laboratory Evaluation Program (CLEP) issued a laboratory permit to Crescendo Bioscience to provide services to physicians in New York. Crescendo Bioscience offers Vectra® DA, a multi-biomarker blood test that measures disease activity in RA by integrating 12 key proteins consistently associated with the biology of RA into one single, objective and quantitative score to help physicians make more informed patient management decisions. With this clearance, Vectra DA is now available in all 50 states.